The Certification Study Guide (6th edition) emphasizes that immediate first aid is the first and most critical step following an occupational exposure to blood or body fluids, including needle-stick injuries. First aid measures include promptly washing the affected area with soap and water and flushing mucous membranes with water if exposed. This immediate action helps reduce the microbial load at the exposure site and may lower the risk of transmission of bloodborne pathogens such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).
The study guide outlines a clear sequence for managing occupational exposures. Initial wound care always precedes risk assessment, documentation, immune status evaluation, and post-exposure prophylaxis decisions.
Delaying first aid to gather information or schedule appointments is inconsistent with best practice and increases potential risk to the exposed worker.
The other options represent appropriate subsequent steps, not first actions. Scheduling an OH appointment and assessing immune status are important but occur after immediate wound care. Discussing the exposure to determine risk level is also essential, but only after first aid has been provided.
CIC exam questions frequently assess understanding of prioritization and sequencing in occupational exposure management. Recognizing that immediate first aid is always the first intervention reflects sound infection prevention practice and aligns with established occupational health protocols.
Reference: Certification Study Guide (CBIC/CIC Exam Study Guide), 6th edition, Chapter 6: Employee
/Occupational Health.

The Certification Study Guide (6th edition) explains that assessment of Mycobacterium tuberculosis (MTB) risk in healthcare settings begins with evaluating the likelihood that patients with active TB will present to the facility. One of the most important determinants of this likelihood is the incidence of active TB disease in the community served by the healthcare facility. Facilities serving populations with higher TB prevalence are at increased risk of exposure events and must tailor their TB prevention and control programs accordingly.
The study guide emphasizes that TB risk assessments are population-based and epidemiologic in nature.
Community TB rates directly influence the frequency with which undiagnosed or unsuspected infectious TB patients may enter the healthcare system, potentially exposing healthcare personnel (HCP) and other patients.
This factor drives decisions regarding surveillance intensity, education, respiratory protection programs, and engineering controls.
The other options represent control measures or outcomes, not primary risk determinants. The number of airborne infection isolation rooms reflects facility preparedness, not exposure risk. Rates of positive HCP screening tests may indicate past exposure but are not used to assess initial risk. Compliance with N-95 fit testing is a program performance indicator, not a measure of TB exposure likelihood.
CIC exam questions commonly distinguish between risk assessment inputs versus mitigation strategies.
Recognizing community TB incidence as the foundational risk factor is essential for accurate TB program planning and compliance with recommended infection prevention standards.
Reference: Certification Study Guide (CBIC/CIC Exam Study Guide), 6th edition, Chapter 6: Employee
/Occupational Health; Chapter 4: Surveillance and Epidemiologic Investigation.

In quality improvement, a baseline measurement is collected before implementing changes so the team can compare performance over time and determine whether interventions produced improvement. Creating the baseline after changes are implemented defeats the purpose of baseline data because it removes the "pre- intervention" reference point needed to evaluate impact and sustainment. Quality improvement measurement guidance emphasizes capturing a baseline and then continuing measurement at regular intervals to judge the effect of an intervention.
The other activities listed are appropriate for standardizing disinfection and sterilization practices. Direct observation (A) is a common process-assessment method to identify gaps between policy and actual practice.
Including central sterile/central supply and OR leaders (B) supports multidisciplinary engagement and ensures changes are operationally feasible where reprocessing occurs. Performing a literature and guidance review (C) helps align local practice with authoritative recommendations (e.g., CDC disinfection/sterilization guidance and monitoring expectations).

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that when evaluating new medical or surgical equipment, the first priority for the infection preventionist is reviewing the manufacturer's instructions for use (IFU). The IFU provides critical information regarding cleaning, disinfection, sterilization, handling, storage, and maintenance requirements, all of which directly impact infection prevention and patient safety.
Robotic surgical equipment often includes complex components, lumens, joints, and reusable instruments that may require specialized reprocessing methods. The IP must ensure that the facility has the infrastructure, staffing, competency, and resources to meet the IFU requirements before purchase. Failure to comply with manufacturer instructions places the organization at risk for ineffective reprocessing, device contamination, healthcare-associated infections, and regulatory noncompliance.
The other options are secondary considerations. Cost (Option A) and operative time impact efficiency and budgeting but do not address infection risk. Storage between cases (Option C) is important but cannot be properly evaluated without first understanding IFU requirements. Length of surgery (Option B) may influence infection risk but is not within the primary evaluative scope of infection prevention during equipment selection.
For the CIC exam, it is essential to recognize that IFU review is the foundational step in product evaluation.
Infection preventionists must confirm that equipment can be safely and consistently reprocessed according to manufacturer specifications before any operational or financial considerations are addressed.

The correct answer is A, "Pregnant persons," as they should be excluded from receiving the live attenuated influenza virus (LAIV) vaccine. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, which align with recommendations from the Centers for Disease Control and Prevention (CDC) and the Advisory Committee on Immunization Practices (ACIP), the LAIV, commonly known as the nasal spray flu vaccine, contains a live attenuated form of the influenza virus. This vaccine is contraindicated in pregnant individuals due to the theoretical risk of the attenuated virus replicating and potentially harming the fetus, despite limited evidence of adverse outcomes (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.2 - Implement measures to prevent transmission of infectious agents).
Pregnant persons are instead recommended to receive the inactivated influenza vaccine (IIV), which is considered safe during pregnancy.
Option B (healthy persons aged 2 to 49) is incorrect because this group is generally eligible to receive LAIV, provided they have no other contraindications, as the vaccine is approved for healthy, non-pregnant individuals in this age range (CDC Immunization Schedules, 2024). Option C (persons with allergies to chicken feathers) is not a contraindication for LAIV; the vaccine is produced in eggs, and while egg allergy was historically a concern, current guidelines indicate that LAIV can be administered to persons with egg allergies if they can tolerate egg in their diet, with precautions managed by healthcare providers. Option D (persons simultaneously receiving an inactivated vaccine) is also incorrect, as LAIV can be co-administered with inactivated vaccines without issue, according to ACIP recommendations, as there is no significant interference between the two vaccine types.
The exclusion of pregnant persons reflects CBIC's emphasis on tailoring infection prevention strategies, including vaccination programs, to protect vulnerable populations while minimizing risks (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.1 - Collaborate with organizational leaders). This decision is based on precautionary principles outlined in CDC and ACIP guidelines to ensure maternal and fetal safety (CDC Prevention and Control of Seasonal Influenza with Vaccines, 2023).
References: CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competencies 3.1 - Collaborate with organizational leaders, 3.2 - Implement measures to prevent transmission of infectious agents. CDC Prevention and Control of Seasonal Influenza with Vaccines, 2023. CDC Immunization Schedules, 2024.